Which is safer, Wegovy or Mounjaro? What the evidence actually shows

Picture this: you've been offered both options and you're trying to work out which carries less risk

It's a question our prescribers hear regularly. Someone has done the research, seen that Mounjaro produced stronger average weight loss in trials, but worries that being more powerful means being more dangerous. That's a reasonable instinct, but it isn't quite how these medicines work.

Wegovy acts on a single receptor pathway: GLP-1, the gut hormone that slows gastric emptying and dials down appetite. Mounjaro adds a second pathway, GIP, making it the only dual-agonist weight-loss medicine licensed in the UK. More pathways does not automatically mean more risk. Both medicines carry a Black Triangle (▼) designation from the MHRA, meaning they're under enhanced monitoring, not because they're unusually dangerous, but because that's standard for newer medicines where ongoing data collection matters. The NHS tirzepatide medicines page and the NHS semaglutide medicines page lay out the side-effect profiles in plain language if you want to read them side by side.

If you're weighing up the risk profiles of the two treatments, our guide to what is safer, Wegovy or Mounjaro, walks through the evidence in detail. The honest short version: their safety signals overlap heavily. Where they differ is in the specific interactions and cautions that matter for individual patients, which is exactly why a prescriber reviews your full picture before any treatment starts.

Where the safety profiles genuinely differ

The side-effect lists for both medicines are dominated by the same GI symptoms: nausea, vomiting, diarrhoea, constipation, reflux, and fatigue are common to both. These tend to be most noticeable when starting or after a dose increase, and usually settle within a week or two. In January 2026, the MHRA issued a Drug Safety Update covering all GLP-1 medicines, highlighting acute pancreatitis as an infrequent but serious risk: severe, persistent stomach pain that may radiate to the back warrants urgent medical attention. That warning applies to Wegovy and Mounjaro equally.

Where the two medicines genuinely diverge is in drug interactions. Tirzepatide (Mounjaro) slows gastric emptying to a greater degree, which can reduce the absorption of oral contraceptive pills. Women using combined or progesterone-only pill contraception should add a non-oral method (condoms, for example) for the first four weeks of Mounjaro treatment and for four weeks after each dose increase. NHS England also recommends considering transdermal HRT for the same reason. For semaglutide (Wegovy), current evidence does not show the same reduction in pill effectiveness, though any interaction question should still be discussed with your prescriber.

If you're considering switching between the two, the considerations around switching from Mounjaro to Wegovy are worth understanding before making any change.

The comparison table: key safety and eligibility facts

The table below summarises the clinically relevant differences. Numbers from NICE appraisals and NHS guidance are cited; everything else reflects the licensed summary of product characteristics.

For a fuller side-by-side look at how the two medicines perform on results and eligibility, the Wegovy vs Mounjaro overview covers the evidence in more depth. And if cost is part of your thinking, our page on tirzepatide vs semaglutide costs in the UK explains the current private pricing landscape honestly.

What this means when you're choosing (and how the conversation with a prescriber actually works

If you're placing your order on a Monday morning) or squeezing it in before a holiday so delivery lands in time, the safety question is worth settling first, before you get to the logistics. Both medicines require an active prescription following a proper clinical review, and that review is where questions like your current medications, your contraceptive method, your GI history, and your previous experience of weight-loss treatment all get assessed properly.

Neither Wegovy nor Mounjaro is right for everyone. Pregnancy, breastfeeding and trying to conceive are contraindications for both. Neither is licensed for under-18s. A personal history of pancreatitis, medullary thyroid carcinoma, or MEN2 requires specific prescriber discussion before either medicine is considered.

The head-to-head trial data from SURMOUNT-5, published in the New England Journal of Medicine in 2025, showed tirzepatide produced greater average weight reduction than semaglutide 2.4mg over 72 weeks, but that finding is about average efficacy in trial populations, not about which is safer for a specific patient. If you're still working through which is better, Mounjaro or Wegovy, or want a closer look at which is best, Mounjaro or Wegovy, for your particular circumstances, both guides are worth reading before your consultation. Our clinical team, including our lead prescriber, review each consultation individually. Which suits you is a clinical decision made together with our prescribers, not a conclusion a comparison table can reach on your behalf.

If you'd like to speak to our prescribers, the consultation is free, takes place the same day, and there is no obligation to proceed.